Sino Biopharmaceutical Limited (FRA:SMZ1)

Market Cap	9.11B
Revenue (ttm)	3.82B
Net Income (ttm)	463.14M
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	19.66
Forward PE	22.54
Dividend	0.01 (1.40%)
Ex-Dividend Date	Sep 10, 2024

Volume	1,054
Average Volume	8,343
Open	0.4939
Previous Close	0.4925
Day's Range	0.4939 - 0.5054
52-Week Range	0.3001 - 0.5088
Beta	n/a
RSI	62.07
Earnings Date	May 16, 2025

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. It offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under An...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 24,379
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SMZ1

Financial Performance

In 2024, Sino Biopharmaceutical's revenue was 28.87 billion, an increase of 10.18% compared to the previous year's 26.20 billion. Earnings were 3.50 billion, an increase of 50.08%.

Financial numbers in CNY